Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.

Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.

J Am Soc Nephrol. 2019 Jun 14. pii: ASN.2019050450. doi: 10.1681/ASN.2019050450. [Epub ahead of print]

PMID:
31201218
2.

Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.

Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK; ZS-005 Study Investigators.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):798-809. doi: 10.2215/CJN.12651018. Epub 2019 May 20.

PMID:
31110051
3.

Anemia in Non-Dialysis-Dependent CKD: To Treat or Not to Treat?

Fishbane S, Ross DW, Hong S.

Am J Kidney Dis. 2019 Mar;73(3):297-299. doi: 10.1053/j.ajkd.2018.11.006. Epub 2019 Jan 5. No abstract available.

PMID:
30616872
4.

Administrative Leadership: Nephrologists in Non-nephrology Leadership Roles.

Gitman M, Bellucci A, Fishbane S.

Adv Chronic Kidney Dis. 2018 Nov;25(6):490-493. doi: 10.1053/j.ackd.2018.07.001. Review.

PMID:
30527547
5.

Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.

Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, Neylan JF, Chertow GM.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1115-1124. doi: 10.1093/ndt/gfy318.

6.

Medication discrepancies in late-stage chronic kidney disease.

Ibrahim J, Hazzan AD, Mathew AT, Sakhiya V, Zhang M, Halinski C, Fishbane S.

Clin Kidney J. 2018 Aug;11(4):507-512. doi: 10.1093/ckj/sfx135. Epub 2017 Nov 23.

7.

Introduction to unresolved issues in the care of dialysis patients.

Mathew AT, Fishbane S.

Semin Dial. 2018 Jul;31(4):313-314. doi: 10.1111/sdi.12736. No abstract available.

PMID:
29978602
8.

Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.

McCullough PA, Uhlig K, Neylan JF, Pergola PE, Fishbane S.

Am J Cardiol. 2018 Aug 15;122(4):683-688. doi: 10.1016/j.amjcard.2018.04.062. Epub 2018 May 19.

9.

Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists.

Mallappallil MC, Fishbane S, Wanchoo R, Lerma E, Roche-Recinos A, Salifu M.

BMC Nephrol. 2018 Jun 22;19(1):147. doi: 10.1186/s12882-018-0943-0.

10.

Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.

Fishbane S, Singh B, Kumbhat S, Wisemandle WA, Martin NE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1204-1214. doi: 10.2215/CJN.11631017. Epub 2018 Jun 19.

PMID:
29921734
11.

Opportunities for Increasing the Rate of Preemptive Kidney Transplantation.

Fishbane S, Nair V.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1280-1282. doi: 10.2215/CJN.02480218. Epub 2018 May 16. No abstract available.

PMID:
29769181
12.

Potentially Avoidable Readmissions in United States Hemodialysis Patients.

Mathew AT, Rosen L, Pekmezaris R, Kozikowski A, Ross DW, McGinn T, Kalantar-Zadeh K, Fishbane S.

Kidney Int Rep. 2017 Nov 3;3(2):343-355. doi: 10.1016/j.ekir.2017.10.014. eCollection 2018 Mar.

13.

Cyclical cardiorenal syndrome in late-stage kidney disease
.

Ku B, Fishbane S.

Clin Nephrol. 2018 Sep;90(3):180-184. doi: 10.5414/CN109322.

PMID:
29701173
14.

Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia.

Pergola PE, Fishbane S, LeWinter RD, Neylan JF, Uhlig K, Block GA, Chertow GM.

Am J Hematol. 2018 Jun;93(6):E154-E156. doi: 10.1002/ajh.25088. Epub 2018 Mar 30. No abstract available.

15.

Is there an established hemoglobin target range for patients undergoing chronic dialysis?

Shah HH, Fishbane S.

Semin Dial. 2018 Jul;31(4):415-419. doi: 10.1111/sdi.12683. Epub 2018 Mar 6. Review.

PMID:
29509320
16.

Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018.

Fishbane S, Spinowitz B.

Am J Kidney Dis. 2018 Mar;71(3):423-435. doi: 10.1053/j.ajkd.2017.09.026. Epub 2018 Jan 11.

PMID:
29336855
17.

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.

Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S.

PLoS One. 2017 Nov 29;12(11):e0188712. doi: 10.1371/journal.pone.0188712. eCollection 2017.

18.

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.

Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Otoguro T, Yamada K, Nagamine Y, Fishbane S, Hirakata H.

Kidney Int Rep. 2017 Jan 5;2(3):359-365. doi: 10.1016/j.ekir.2016.12.005. eCollection 2017 May.

19.

A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin.

Koncicki HM, Fishbane S.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1173-1175. doi: 10.2215/CJN.01160117. Epub 2017 May 18. No abstract available.

20.

Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial.

Fishbane S, Agoritsas S, Bellucci A, Halinski C, Shah HH, Sakhiya V, Balsam L.

Am J Kidney Dis. 2017 Oct;70(4):498-505. doi: 10.1053/j.ajkd.2017.02.366. Epub 2017 Apr 7.

PMID:
28396108
21.

Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.

Fishbane S, Shah HH.

Hemodial Int. 2017 Jun;21 Suppl 1:S104-S109. doi: 10.1111/hdi.12554. Epub 2017 Apr 3. Review.

PMID:
28371161
22.

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.

Locatelli F, Fishbane S, Block GA, Macdougall IC.

Am J Nephrol. 2017;45(3):187-199. doi: 10.1159/000455166. Epub 2017 Jan 25. Review.

23.

Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.

Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, Chertow GM.

J Am Soc Nephrol. 2017 Jun;28(6):1851-1858. doi: 10.1681/ASN.2016101053. Epub 2017 Jan 12.

24.

Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.

Winkelmayer WC, Goldstein BA, Mitani AA, Ding VY, Airy M, Mandayam S, Chang TI, Brookhart MA, Fishbane S.

Am J Kidney Dis. 2017 Jun;69(6):771-779. doi: 10.1053/j.ajkd.2016.10.031. Epub 2017 Jan 4.

25.

What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Role for Newly Approved Iron Treatments.

Fishbane S.

Semin Dial. 2017 Jan;30(1):27-29. doi: 10.1111/sdi.12551. Epub 2016 Sep 29. No abstract available.

PMID:
27687015
26.

Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.

Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S.

Kidney Int Rep. 2016 Sep 21;2(1):108-123. doi: 10.1016/j.ekir.2016.09.055. eCollection 2017 Jan. Review.

27.

Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Wish JB, Charytan C, Chertow GM, Kalantar-Zadeh K, Kliger AS, Rubin RJ, Yee J, Fishbane S.

Am J Kidney Dis. 2016 Dec;68(6):843-852. doi: 10.1053/j.ajkd.2016.06.022. Epub 2016 Sep 3.

PMID:
27599628
28.

Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System.

Jhaveri KD, Sakhiya V, Wanchoo R, Ross D, Fishbane S.

Kidney Int. 2016 Sep;90(3):706-7. doi: 10.1016/j.kint.2016.06.027. No abstract available.

PMID:
27521117
29.

Epidemiology and Challenges to the Management of Advanced CKD.

Hazzan AD, Halinski C, Agoritsas S, Fishbane S, DeVita MV.

Adv Chronic Kidney Dis. 2016 Jul;23(4):217-21. doi: 10.1053/j.ackd.2016.04.005. Review.

PMID:
27324673
30.

Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.

Shah HH, Hazzan AD, Fishbane S.

Semin Nephrol. 2016 Mar;36(2):124-9. doi: 10.1016/j.semnephrol.2016.02.007. Review.

PMID:
27236134
31.

Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.

Fishbane S.

Semin Nephrol. 2016 Mar;36(2):119-23. doi: 10.1016/j.semnephrol.2016.02.006. Review.

PMID:
27236133
32.

Introduction: Iron Management in Chronic Kidney Disease.

Fishbane S.

Semin Nephrol. 2016 Mar;36(2):85-6. doi: 10.1016/j.semnephrol.2016.02.009. No abstract available.

PMID:
27236127
33.

Preservation of residual kidney function in hemodialysis patients: reviving an old concept.

Mathew AT, Fishbane S, Obi Y, Kalantar-Zadeh K.

Kidney Int. 2016 Aug;90(2):262-271. doi: 10.1016/j.kint.2016.02.037. Epub 2016 May 12. Review.

34.

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.

Rostoker G, Vaziri ND, Fishbane S.

Drugs. 2016 May;76(7):741-57. doi: 10.1007/s40265-016-0569-0. Review.

35.

Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis.

Fishbane S, Hazzan AD, Jhaveri KD, Ma L, Lacson E Jr.

Clin J Am Soc Nephrol. 2016 Jun 6;11(6):1063-72. doi: 10.2215/CJN.09280915. Epub 2016 Mar 29.

36.

Recipient Criteria Predictive of Graft Failure in Kidney Transplantation.

Molmenti EP, Alex A, Rosen L, Alexander M, Nicastro J, Yang J, Siskind E, Alex L, Sameyah E, Bhaskaran M, Ali N, Basu A, Sachdeva M, Agorastos S, Rajendran P, Krishnan P, Ramadas P, Amodu L, Cagliani J, Rehman S, Kressel A, Sethna CB, Sotiropoulos GC, Radtke A, Sgourakis G, Schwarz R, Fishbane S, Bellucci A, Coppa G, Rilo H, Molmenti CL.

Int J Angiol. 2016 Mar;25(1):29-38. doi: 10.1055/s-0035-1563605. Epub 2015 Sep 15.

37.

Update on the End-Stage Renal Disease Quality Incentive Program.

Wanchoo R, Hazzan AD, Fishbane S.

Semin Dial. 2016 Mar-Apr;29(2):144-7. doi: 10.1111/sdi.12463. Epub 2016 Jan 12.

PMID:
26756666
38.

Reducing hospital readmissions in patients with end-stage kidney disease.

Mathew AT, Strippoli GF, Ruospo M, Fishbane S.

Kidney Int. 2015 Dec;88(6):1250-1260. doi: 10.1038/ki.2015.307. Epub 2015 Oct 14. Review.

PMID:
26466320
39.

Weight trends in United States living kidney donors: Analysis of the UNOS database.

Sachdeva M, Rosen LM, Varghese J, Fishbane S, Molmenti EP.

World J Transplant. 2015 Sep 24;5(3):137-44. doi: 10.5500/wjt.v5.i3.137.

40.

Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.

Szebeni J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Rampton D, Weiss G, Folkersen J.

Br J Pharmacol. 2015 Nov;172(21):5025-36. doi: 10.1111/bph.13268. Epub 2015 Oct 25. Review.

41.

Outcomes following Kidney transplantation in IgA nephropathy: a UNOS/OPTN analysis.

Kadiyala A, Mathew AT, Sachdeva M, Sison CP, Shah HH, Fishbane S, Jhaveri KD.

Clin Transplant. 2015 Oct;29(10):911-9. doi: 10.1111/ctr.12594. Epub 2015 Aug 24.

PMID:
26190417
42.

Quality Measurement in Wonderland: The Curious Case of a Dialysis Readmissions Measure.

Fishbane S, Wish JB.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):190-4. doi: 10.2215/CJN.02770315. Epub 2015 Jul 16. Review.

43.

Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.

Jhaveri KD, Sakhiya V, Fishbane S.

JAMA Oncol. 2015 Nov;1(8):1133-4. doi: 10.1001/jamaoncol.2015.1713.

PMID:
26182194
44.

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.

Fishbane SN, Singh AK, Cournoyer SH, Jindal KK, Fanti P, Guss CD, Lin VH, Pratt RD, Gupta A.

Nephrol Dial Transplant. 2015 Dec;30(12):2019-26. doi: 10.1093/ndt/gfv277. Epub 2015 Jul 13.

45.

Novel iron-based phosphate binders in patients with chronic kidney disease.

Shah HH, Hazzan AD, Fishbane S.

Curr Opin Nephrol Hypertens. 2015 Jul;24(4):330-5. doi: 10.1097/MNH.0000000000000128. Review.

PMID:
26050119
46.

On the safety of intravenous iron, evidence trumps conjecture.

Auerbach M, Adamson J, Bircher A, Breymann C, Fishbane S, Gafter-Gvili A, Gasche C, Gilreath J, Grazzini G, Henry D, Liumbruno G, Locatelli F, Macdougall I, Munoz M, Rampton D, Rodgers G, Shander A.

Haematologica. 2015 May;100(5):e214-5. doi: 10.3324/haematol.2014.121004. No abstract available.

47.

Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.

Charytan DM, Fishbane S, Malyszko J, McCullough PA, Goldsmith D.

Am J Kidney Dis. 2015 Aug;66(2):196-205. doi: 10.1053/j.ajkd.2014.12.016. Epub 2015 Feb 26. Review.

48.

Challenges and opportunities in late-stage chronic kidney disease.

Fishbane S, Hazzan AD, Halinski C, Mathew AT.

Clin Kidney J. 2015 Feb;8(1):54-60. doi: 10.1093/ckj/sfu128. Epub 2014 Dec 2.

49.

The emerging role of biosimilar epoetins in nephrology in the United States.

Fishbane S, Shah HH.

Am J Kidney Dis. 2015 Apr;65(4):537-42. doi: 10.1053/j.ajkd.2014.11.018. Epub 2015 Jan 10.

PMID:
25582283
50.

Considerations and challenges in defining optimal iron utilization in hemodialysis.

Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology.

J Am Soc Nephrol. 2015 Jun;26(6):1238-47. doi: 10.1681/ASN.2014090922. Epub 2014 Dec 26. Review.

Supplemental Content

Loading ...
Support Center